Supplementary materials.docx (234.73 kB)
Supplementary materials: Cost-effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma.docx
dataset
posted on 2021-12-09, 09:19 authored by Tanja Podkonjak, Holly Cranmer, Julia Scarisbrick, Grant McCarthy, Cameron Lilley, Lung-I Cheng
Table A1. Clinical Inputs. Table A2. Cost Inputs. Table A3: Resource utilization. Table A4. Utility inputs. |